Your VUS backlog is
growing.
Your interpretation tools
are not.
for genomics professionals who want to discover multidimensional
relationship scenarios that conventional interpretation tools may never
surface.
Sequencing got cheap.
Interpretation didn't.
Whole-exome sequencing now produces thousands of variants per patient. Many remain classified as Variants of Uncertain Significance — and the backlog grows faster than teams can develop enough evidence to interpret them.
Standard AI and bioinformatics tools often depend on large, clean, normalized datasets. Real-world genomic discovery frequently depends on small, wide, sparse evidence where the most valuable signal appears as an unexpected relationship scenario.
The VUS backlog requires more than another prediction score. It requires a way to reveal contextually relevant relationship scenarios that researchers can evaluate as potential evidence pathways.
Years — industry consensus time to reclassify the current VUS backlog (ACMG 2024)
Genotype-phenotype relationship space with potential RA relevance — much of it invisible to conventional tools
Dark-data signal rate — in published studies, relationship evidence surfaced by the RKE engine was missed entirely by conventional bioinformatics and AI platforms
A biomimetic digital
twin ecosystem
Unlike statistical prediction tools, the VUS Discovery Module focuses on differentiated results: multidimensional relationship scenarios that connect genotype, phenotype, and patient context in ways conventional tools often cannot reveal. The goal is not to explain processing. The goal is to help researchers see new evidence pathways.
Genotype
Upload patient exome CSV files. The engine discovers multidimensional relationship scenarios across your data, and ranks the scenarios by prevalence — no normalization required.
Phenotype
Define the phenotype context you believe matters. The module reveals relationship scenarios that connect variants to the disease-relevant dimensions you want to evaluate.
Patient
Add patient-context dimensions when relevant to reveal broader relationship scenarios across clinical, phenotypic, and genomic evidence.
Start with the phenotype, cohort, or VUS interpretation challenge you want to explore.
Bring your domain expertise to the evidence dimensions that may shape interpretation.
See patterns and candidate relationships that may be invisible to standard approaches.
Review scenarios by prevalence, contextual relevance, and discovery potential.
Use the results to guide hypothesis development, evidence review, and future validation.
Not a prediction engine.
A discovery engine.
Depends on large, normalized datasets — rare disease and small-cohort questions are often under-served
Can miss unexpected relationship signals — the most important discovery cues may sit outside standard assumptions
Produces prediction scores rather than contextually relevant relationship scenarios
Limited evidence transparency — difficult to evaluate why a relationship matters
Variant consequence focus — limited ability to reveal broader genotype-phenotype-patient relationship scenarios
Reveals scenarios in small, wide, sparse evidence — useful where conventional tools may lack sufficient signal
Finds signal in unexpected places — dark-data relationships become visible for expert review
Discovery scenarios, not predictions — results are framed for expert evaluation, not automated classification
Reproducible discovery evidence — scenarios can be revisited, reviewed, and compared across research questions
Contextual relationship evidence — supports stronger hypotheses for future interpretation and validation work
Published before it launched.
Validated in the field.
Biomimetic Digital Twins and Multiomics Applications to Rheumatoid Arthritis and VUS Reclassification
Kearns WG, Glick J, Baisch L, et al. — Genzeva, LumaGene, RYLTI, Qiagen Digital Insights.
25 patient samples · 25 controls · Whole-exome NGS
RA finding: 3,172 VUS-related relationship candidates were surfaced in patient samples. Dark-data relationship signal emerged across 6 genes — HIF1A, HLA-DOA, PTGER3, HIPK3, TGFBR3, HIF1A-AS3 — beyond what standard bioinformatics platforms revealed.
Knowledge Engineering via Biomimetic Digital Twin Ecosystem, Phenotype-Driven Variant Analysis, and Exome Sequencing
Kearns WG, Stamoulis G, Glick J, et al. — Genzeva, Qiagen, RYLTI, Brigham & Women’s Hospital / Harvard.
12 patient samples · matched controls · Endometriosis
Endometriosis finding: a VUS-related relationship scenario involving MUC20 appeared across all 12 patient samples, suggesting a potential biomarker path for future diagnostic research. A chromosomal hotspot was also reported on the short arm of chromosome 8.
Three audiences.
One accelerated evidence engine.
De-risk drug targets before Phase I
Discover multidimensional relationship scenarios relevant to your target phenotype — even when large population cohorts or conventional normalized datasets are unavailable.
- Surface hidden genotype-phenotype-patient relationship scenarios
- Generate contextual evidence pathways for target validation review
- Strengthen early hypotheses with multidimensional discovery evidence
- Accelerate biomarker identification for companion diagnostics
Turn a VUS into an actionable variant
Clinical lab directors face immense pressure to evaluate VUSs. The module helps surface defendable relationship scenarios — not statistical predictions — for expert review and future evidence development.
- Reveal candidate relationship scenarios for deeper review
- Generate traceable evidence pathways for interpretation teams
- Support more informed reclassification research workflows
- Reduce the time-to-answer for clinically urgent cases
Publication-ready causal insights, faster
Two peer-reviewed publications in the Journal of Molecular Diagnostics demonstrate what becomes possible when discovery is organized around multidimensional relationship scenarios rather than prediction alone.
- Discover dark-data relationship signals invisible to existing platforms
- Explore discovery questions in small-cohort research settings
- Use reproducible discovery scenarios to guide replication
- Extend findings to any complex disease phenotype
Not just early access.
Early influence.
We are inviting a limited cohort of genomics professionals to evaluate the VUS Discovery Module, provide feedback, and help shape how multidimensional relationship scenarios are presented for real-world research and interpretation use.
Founding researcher benefits
- Complimentary beta access
- Guided onboarding focused on discovery outcomes
- Direct feedback sessions with the RYLTI team
- Opportunity to influence how results are presented to researchers
- Eligibility for future research collaboration
Preferred beta participants
- Clinical geneticists and molecular pathologists
- Rare disease and translational researchers
- Clinical laboratory and diagnostic teams
- Biotech and pharmaceutical genomics groups
- Researchers with active VUS interpretation projects
Limited founding cohort
Target founding cohort: 50 genomics professionals. We will prioritize applicants with active research questions, VUS interpretation needs, or strong feedback potential.
- No credit card required
- Institutional and commercial emails accepted
- Sample data available if your data is not ready
Beta access is complimentary.
Plans scale after launch.
During the founding beta, accepted participants receive complimentary access. The tiers below preview how access may be structured after beta based on evaluation, proof-of-concept, and professional research use.
For learning, evaluation, and sample-data exploration.
- Sample VUS discovery scenarios
- Guided VUS discovery walkthrough
- Patient, Phenotype, and Genotype relationship perspectives
- 1 active project
- Community and educational support
- Designed for researchers evaluating discovery outcomes
For proof-of-concept studies focused on your own discovery questions.
- Evaluate your own cohort-level discovery questions
- Full VUS Discovery experience
- Relevant evidence-dimension selection
- Exportable discovery scenarios and visual review
- 1 active project per month · previous projects archived as read-only
- Beta feedback participation and onboarding support
For clinical, academic, and commercial research teams.
- Unlimited projects and patient cohorts
- Patient-context relationship expansion
- Custom expert-dimension modeling
- Discovery Studio for iterative scenario exploration
- Priority access for advanced discovery studies
- HIPAA-capable deployment options
- AWS Marketplace billing support
All plans lead to one action during beta: Apply for Founding Beta Access.
Help define the next generation
of VUS discovery.
We are accepting a limited number of genomics professionals into our Founding Beta Program. Accepted participants receive complimentary beta access, guided onboarding, and the opportunity to shape how multidimensional relationship scenarios are delivered to researchers.
your.name@institution.edu
Preference given to active genomics, VUS, rare disease, clinical lab, biotech, pharma, and translational research teams · No credit card required